<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888511</url>
  </required_header>
  <id_info>
    <org_study_id>09.02</org_study_id>
    <nct_id>NCT00888511</nct_id>
  </id_info>
  <brief_title>Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer</brief_title>
  <acronym>TARLAL</acronym>
  <official_title>Concomitant Tarceva® and Irradiation in Patients in Local-regionally Advanced Non-small Cell Lung Cancer. A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olfred Hansen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in
      inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the
      phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy
      (2 Gy x 33 F, 5 F per week).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local failure free survival at 9 months after start of radiotherapy evaluated at CT scan</measure>
    <time_frame>May 2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>May 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tumor control by CT-scan</measure>
    <time_frame>May 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (CR + PR)</measure>
    <time_frame>May 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tumor control at 9 months evaluated by PET-CT</measure>
    <time_frame>May 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>May 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>May 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>May 2012</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarceva</intervention_name>
    <description>Tarceva 150 mg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>66 Gy/33 F/5 F per week for 5 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Patients with histologically or cytologically documented diagnosis locally advanced
             NSCLC stage IIB to IIIB without pleural effusion

          -  Performance status ≤2 on the ECOG scale

          -  Serum bilirubin must be ≤1.5 upper limit of normal (ULN)

          -  ALAT ≤2 x ULN

          -  Able to comply with study and follow-up procedures

          -  Patients with reproductive potential must use effective contraception

          -  Written (signed) informed consent to participate in the study

        Exclusion Criteria:

          -  Any unstable systemic disease (including active infection, unstable angina, congestive
             heart failure, severe hepatic, renal, or metabolic disease)

          -  Any other malignancies within 5 years (except for adequately treated carcinoma in situ
             of the cervix or basal or squamous cell skin cancer)

          -  Inability to take oral medication, or requirement of intravenous alimentation

          -  Nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olfred Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Copenhagen University Hospital at Herlev</name>
      <address>
        <city>Herlev</city>
        <zip>270</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratory of Radiation Physics</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Olfred Hansen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Tarceva</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Local-regionally advanced non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 6, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>April 7, 2017</submitted>
    <returned>June 23, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

